U.S. Stock Market Update: Windtree Therapeutics down 10.66%

U.S. Stock Market Midday Update Windtree Therapeutics, down 10.66%, with increased trading volume. Based on recent key news: On August 15, Elliott Investment Management dissolved its shares in Windtree Therapeutics, leading to a decline in market confidence and a 10.66% drop in stock price. On August 14, the Securities and Exchange Commission released a negative report on Windtree Therapeutics, further undermining investor confidence. On August 16, market rumors suggested that a key drug trial for Windtree Therapeutics had failed, resulting in a significant drop in stock price. Top Stocks by Industry Trading Volume Propanc Biopharma rose 185.76%, with a trading volume of $266 million. Based on recent important news: On August 15, Propanc Biopharma successfully raised $4 million by issuing 1 million shares, driving a significant increase in stock price. On August 13, a block trade occurred in Kintor Pharmaceutical, with a transaction amount of 4.4766 million yuan, leading to a slight increase in stock price. On August 18, Neusoft Carrier announced a strategic investment plan, maintaining stable stock prices despite cost pressures. Soligenix rose 60.07%, with increased trading volume. Based on recent important news: On August 18, Soligenix announced that its drug for treating Behçet's disease received FDA orphan drug designation, causing a 57% increase in stock price. On August 18, Soligenix's SGX945 showed significant efficacy in Phase II clinical trials, with a positive market response. On August 16, Soligenix received a notice from Nasdaq regarding non-compliance with equity requirements, but it did not negatively impact the stock price. Bioxcel Therapeutics rose 13.89%, with increased trading volume. Based on recent important news: On August 18, BioXcel Therapeutics announced that its drug BXCL501 received positive feedback from the FDA, planning to submit a market application in Q1 2026, driving a 26.5% increase in stock price. On August 16, HC Wainwright & Co. raised the target price for BioXcel Therapeutics from $8 to $10, boosting market confidence. On August 15, BioXcel Therapeutics released important information through the EDGAR system, further increasing investor attention. Top Stocks by Industry Market Capitalization AbbVie rose 0.45%, with a market capitalization of $366.8 billion. Based on recent important news: On August 15, Point72 Hong Kong Ltd. initiated a new position in AbbVie in the second quarter, demonstrating confidence in the stock and driving its price up. On August 18, AbbVie's dividend yield was 3.2%, significantly higher than the average level of the S&P 500, attracting more investor attention. On August 17, although analysts rated AbbVie as a moderate buy, it was not listed as a top recommended stock, limiting further price increases